Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
ROIV•Topline results from proof-of-concept study
Roivant Sciences Ltd ROIV.O:
- Roivant announces topline results from proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus.
- Roivant Sciences - IMVT-1402 study in CLE did not achieve statistical significance on primary endpoint.
- Roivant Sciences - Immunovant to stop development of IMVT-1402 in CLE.
- Roivant Sciences - IMVT-1402 demonstrates favorable safety and tolerability profile.
- Roivant Sciences - All other clinical development timelines remain on track.
